Skip to content
Open access

Decoding Treatment Response and Prognosis in Unresectable Locally Advanced Non–Small Cell Lung Cancer by Integrating Spatiotemporal Heterogeneity From 18F-FDG Positron Emission Tomography-Computed Tomography: A Multicenter Study

Oct 2026 · JCO Precision Oncology · Vol 10 · 0 citations · 27 references
Medicine

TL;DR

This study establishes a noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT that reliably predicts treatment response and prognostic outcomes in unresectable LA-NSCLC and offers valuable insights for personalized clinical decision making and supports precision oncology.

Abstract

Purpose Treatment response in unresectable locally advanced non–small cell lung cancer (LA-NSCLC) is highly variable due to marked intratumoral heterogeneity, while existing predictive biomarkers lack accuracy. We aimed to develop and validate a pretreatment 18F-FDG positron emission tomography (PET)-computed tomography (CT)–derived spatiotemporal heterogeneity model to predict treatment response and prognosis in unresectable LA-NSCLC, and to explore its biological underpinnings. Materials and Methods In a multicenter cohort of 434 patients with unresectable LA-NSCLC (training: n = 215; internal validation: n = 93; external validation: n = 126), treatment response was classified as responsive or nonresponsive based on initial assessment. Four distinct habitats (PEThigh-CThigh, PETlow-CTlow, PETlow-CThigh, and PEThigh-CTlow) were generated via the Otsu algorithm. Temporal heterogeneity was quantified using metabolic hotspot displacement (normalized distance from the hotspot to the tumor centroid and normalized distance from the hotspot to the tumor periphery) and integrated with spatial radiomics to build a multidimensional spatiotemporal model. Model performance was evaluated against conventional metrics, with interpretability enhanced via nomogram and SHapley Additive exPlanations analysis. Survival outcomes were assessed using Kaplan-Meier curves, and public transcriptomic data were analyzed to characterize underlying pathways. Results The spatiotemporal model accurately predicted treatment response with AUCs of 0.822 (training), 0.821 (internal validation), and 0.810 (external validation), significantly outperforming conventional whole-tumor PET-CT models. It maintained robust generalizability across treatment subgroups and effectively stratified patients by progression-free survival and overall survival (P < .01). PEThigh-CThigh habitat volume fraction correlated with treatment resistance, whereas PETlow-CTlow habitat correlated with better response. Exploratory pathway analysis highlighted key pathways involving drug metabolism, glycolytic reprogramming, and immune microenvironment remodeling. Conclusion This study establishes a noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT that reliably predicts treatment response and prognostic outcomes in unresectable LA-NSCLC. It offers valuable insights for personalized clinical decision making and supports precision oncology.

Read PDF

Similar papers

Open access Oct 2026

Development and validation of a deep learning model integrating 18F-FDG PET/CT radiomics and clinical features to predict major pathological response in non-small cell lung cancer patients receiving chemoimmunotherapy

Background Pathological complete response (pCR) and major pathological response (MPR) are early measures of treatment efficacy with prognostic relevance in patients with non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy. Individual biomarkers such as programmed cell death-ligand 1 (PD-L1) and...

Ao Li, Zi-Hao Mao, Hai-Long Wang et al. · 0 citations
Review Open access Oct 2026

18F-FDG PET/CT radiomics across treatment timepoints for predicting response to neoadjuvant therapy in locally advanced esophageal cancer: a systematic review and meta-analysis

Pathological complete response (pCR) after neoadjuvant therapy is achieved in only about 20%–40% of patients with locally advanced esophageal cancer (LAEC), yet it is the strongest determinant of long-term survival. 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT)...

Jie Li, S. Suppiah, Lingeswaran Kasilingam et al. · 0 citations
Oct 2026

Prognostic Value of 68Ga-NOTA-AE105 uPAR PET/CT in Resected Non-Small Cell Lung Cancer: A Single-Center Prospective Study.

It is suggested that uPAR PET captures invasion-related tumor biology that is not fully reflected by glucose metabolism imaging that is not fully reflected by glucose metabolism imaging in non-small cell lung cancer.

P. Soldath, M. Clausen, Annika Loft et al. · 0 citations
Oct 2026

Pretreatment FDG-PET Biomarkers Predict Regional and Distant Failure but Not Local Recurrence Following Modern Use of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.

BACKGROUND Quantitative fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers are associated with prognosis following stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (ES-NSCLC); however, their relationship with patterns of failure remains poorly defined. We evaluated the...

D. Jayamanne, J. Chan, Riche Mohan et al. · 0 citations
Open access Aug 2026

18F-FDG PET/CT Habitat Radiomics for Predicting Epidermal Growth Factor Receptor Mutation Status in Locally Advanced Non-small Cell Lung Cancer: A Multicenter Study.

IntroductionAccurate identification of epidermal growth factor receptor mutation status is essential for treatment planning in locally advanced non-small cell lung cancer, but tissue testing may be limited by specimen availability and sampling. We developed and externally validated a fluorine-18 fluorodeoxyglucose posi...

Hao-Ran Lian, Hai-Feng Deng, Jing-Song Zheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.